Azacitidine

Red

Brand Name(s):Vidaza

Indication:Myeloid leukaemia (Acute), Myelodysplastic syndromes. Chronic or Acute myelomonocytic leukaemia

Rationale:1,2,3

Considered:Jan-08

Review Date:Aug-21

Comments:
NICE TA399 Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts – does not recommend in this group
July 2016
…………………………
NICE recommends azacitidine as a possible treatment for some adults with myelodysplastic syndromes, chronic myelomonocytic leukaemia or acute myeloid leukaemia. Who can have azacitidine?

People who cannot have a stem cell transplant may be able to have azacitidine. Azacitidine is ‘licensed’ (approved as being safe by the European regulatory agency) for adults with myelodysplastic syndromes, chronic myelomonocytic leukaemia or acute myeloid leukaemia, but only in specific circumstances, for example, depending on the characteristics of the person’s blood and bone marrow.

NICE TA218 March 2011